Conversion of Convertible Loan Notes

6 May 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Conversion of Convertible Loan Notes

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that the Company has received a notice to convert £400,000 of convertible loan notes ("CLNs") held by Frazer Lang (registered in the name of Ropemaker Nominees Limited) (the "Note Holder"), an existing investor in the Company.

On 20 May 2025, the Company secured funding of £150,000 through the issue of CLNs to Frazer Lang and the funding provided by him was extended though the issue of further CLNs of £250,000 on 5 November 2025. The CLNs are convertible at the election of the Note Holder into new ordinary shares of 0.01p in the Company ("Ordinary Shares") at a price of 1.4 pence per Ordinary Share. Following receipt of the conversion notice the Company will therefore issue 28,571,429 new Ordinary Shares ("Conversion Shares") to the Note Holder.

In addition, the Company announced on 2 April 2026 that it has entered into a new facility to provide the Company with up to £250,000 through the potential issue of further unsecured convertible loan notes ("Facility Notes") to the Note Holder. The Facility Notes can be drawn down, at the sole election of the Company as to £100,000 on 1 May 2026, £100,000 on 1 June and £50,000 on 1 July 2026. The Facility Notes are convertible at 1.4 pence per Ordinary Share at any time up to 30 October 2026. The Company has now drawn down £100,000 of the Facility Notes and following completion of the £400,000 CLN conversion, the Note Holder will hold £100,000 of CLNs.

Admission and Total Voting Rights

Application will be made for the 28,571,429 Conversion Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing on the FCA Official List ("Admission"). It is expected that the issue of the 28,571,429 Conversion Shares will take place, Admission will become effective and that dealings in the Conversion Shares on the Main Market of the London Stock Exchange will commence on or around 11 May 2026.

On Admission, the Company will have 424,963,202 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares and voting rights will be 424,963,202 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

About Cizzle Biotechnology

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021. 

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.